Center for Infectious Disease Research

Dr. Hakami co-chaired the first-in-kind “EVs in Immunity” symposium

Last year, Dr. Hakami co-chaired the first-in-kind “EVs in Immunity” symposium in Athens, Greece, alongside Dr. Clotilde Théry, a pioneering global leader in extracellular vesicle (EV) research. Hosted by the International Society for Extracellular Vesicles (ISEV), the conference was a resounding success. It brought together 214 participants, featured 36 outstanding talks by prominent experts, and showcased 123 poster presentations. 

George Mason University and Phase Inc. receive NSF grant to advance 3D-printed microfluidic technology

NSF funding grant awarded to Dr. Ramin M. Hakami and Dr. Remi Veneziano (Bioengineering Department) for extracellular vesicle studies

Ramin M. Hakami and Remi Veneziano. Photo provided
Ramin M. Hakami and Remi Veneziano. Photo provided

George Mason University and Phase Inc. have received a National Science Foundation (NSF) STTR grant to advance a new generation of 3D-printed microfluidic devices that could help move the technologies from the research lab toward broader commercial and scientific use.

The project combines the expertise of College of Science Professor Ramin M. Hakami’s group in extracellular vesicle (EV) biology, and that of College of Engineering and Computing Associate Professor Remi Veneziano’s group in bioengineering and materials characterization, at George Mason University with Phase’s vision to create an end-to-end, automated microfluidic platform that brings together custom device design, scalable 3D-printed polydimethylsiloxane (PDMS) chip manufacturing, and automated fluid handling. Specifically, this project leverages the microfluidic EV platform jointly developed and published by the Veneziano and Hakami groups.

Read the Full Article Here..

Dr. Hakami delivered the opening address at EVOLVE 2026

Dr. Hakami delivered the opening address at EVOLVE 2026, the second annual conference of the Indian Society for Extracellular Vesicles (InSEV). Hosted by BRIC-ILS in Bhubaneswar, India, the premier event gathered leading investigators to share cutting-edge research in extracellular vesicle biology. 

#FacultyFriday congratulates Monique van Hoek!

This #FacultyFriday congratulates Monique van Hoek, a professor in the School of Systems Biology, for earning the Dean’s Big Challenge Award! van Hoek pioneers innovative solutions to combat antibiotic-resistant bacteria using antimicrobial peptides. Her latest discovery, GATR-3—derived from an alligator peptide—has shown remarkable effectiveness in killing some of the most resistant bacteria responsible for chronic wound infections. This breakthrough holds significant promise for patients with conditions like diabetes and soldiers with severe wounds, offering new treatment options for difficult-to-treat infections.

In collaboration with Barney Bishop from the Department of Chemistry and Biochemistry, van Hoek has advanced GATR-3 through pre-clinical testing with support from the Joint Warfighter Program. With more than 60 publications and five patents, she is a recognized leader in her field. van Hoek also mentors 15 to 20 graduate students annually in her lab at the Center for Infectious Disease Research.

Recently, she and her collaborators received a Virginia Catalyst grant to develop a hydrogel for delivering antibiotics to surgical and orthopedic infections, further expanding her impact in the fight against bacterial resistance.

Learn more about van Hoek and all our Dean’s award winners: https://lnkd.in/eDTn_i_t

Kashanchi lab has obtained fundings on HIV, HTLV and EV diagnostic and therapeutic research

Kashanchi lab has recently obtained multiple fundings on HIV, HTLV and EV diagnostic and therapeutic research. The fundings total more than a million dollars a year for multiple years and are from NIH, Campbell Foundation, and DOD. The topics range from silencing of HIV in the brains of infected individuals; detection of EVs from gut microbiome and its connection to CNS in HIV patients (Collaboration with University of Miami); Use of EVs from Babesia infected cells for vaccines (Collaboration with Yale and ATCC); Use of immune therapy on HTLV-1 infected cells; and detection of specific modified RNA in HIV-1 infected cells (Collaboration with Harvard).

Mason Science Series: Treating the Next Pandemic Using Your Own Immune System

Dr. Hakami is the featured guest for the next Mason Science Series event hosted by the College of Science Dean Fernando Miralles-Wilhelm. Dr. Hakami will discuss his novel research into the regulation of immunity by extracellular vesicles (EVs) and also the development and characterization of a novel nanoparticle-based therapeutic platform called NESTED for treating infectious diseases. For more details, please go to the following link:

https://science.gmu.edu/UpcomingMSS

Dr. Ramin M. Hakami has received an $80,000 grant from the Henry Klopp Trust

Dr. Ramin M. Hakami has received an $80,000 grant from the Henry Klopp Trust for studies of how a novel nanoparticle-based platform called NESTED provides protection against infectious diseases

The van Hoek lab gives two talks at the upcoming Spring 2024 meeting of the Washington, D.C Branch of the American Society for Microbiology (ASM)

The van Hoek lab gives two talks at the upcoming Spring 2024 meeting of the Washington, D.C. Branch of the American Society for Microbiology (ASM). https://www.washingtondcasm.org/

Doctoral students Ashley Carpenter and Lulu Alsalih’s joint abstract has been selected for a Lightning Talk. 

Post-doc Sarah Alobaid’s abstract has been selected for an early career talk.  

The Meeting is April 12th at Howard University.

https://www.washingtondcasm.org/2024springmeeting 

George Mason COS #Faculty Friday – Yuntao Wu

This #FacultyFriday features Yuntao Wu, Professor,

He has been studying viruses for over 30 years, and for the past 20 years, he has been primarily focused on studying HIV infection. Read below to learn about his research, and visit:

https://science.gmu.edu/directory/yuntao-wu

Mason scientists explore innovative approach to silence HIV in the central nervous system, encourage scientific collaboration

Research team receives $2.95M in NIH funding to study cell-derived extracellular vesicle mediated epigenetic HIV silencing in the brain.

Read the full Article Here

Dr. Kashanchi

A collaboration including researchers from the Center for Infectious Disease Research at George Mason University is developing and characterizing a highly innovative modular approach that will utilize extracellular vesicles to deliver anti-HIV genes to virus-infected cells in the brain in an effort to epigenetically silence HIV expression in a long-term and stable manner.

Fatah Kashanchi, professor of Virology and Director of the Mason Science Laboratory of Molecular Virology, is the primary investigator on the National Institutes of Health funded collaboration which also includes Mason researchers, Yuriy Kim, Anastasia Marie Williams, and Heather Branscome; Lenny Schultz, a professor from The Jackson Laboratory; and Mason Science affiliate faculty, Kevin Morris, professor and director at The Griffith University Cell and Gene Therapy Group, Menzies Health Institute School of Pharmacology and Medical Sciences, in Queensland, Australia.

The methodology incorporates extracellular exosome delivery. Kashanchi said the effort could be likened to a package delivery. “The team is creating packages that are sent directly to a specific address within the central nervous system, perhaps to the brain ‘zip code’ or to the lymph nodes.” This package will change the actual structure of that viral  genome in the way it twists and turns so it can no longer be active. “For example, think of a normal double helix, then change the structure so that DNA is no longer usable, effectively silencing it with no side effects,” Kashanchi said. This silencing period would be in effect for the individual’s lifetime.

This method may also lead to a therapeutically relevant means to not only control HIV/HAND, (HAND is an HIV associated neurocognitive disorder that impacts memory and thinking), but could usher in a new highly innovative methodology that controls the epigenetic state of those genes involved in various other human diseases.

Kashanchi received $631,369 of the anticipated $2.95M from the National Institutes of Health for this research. Funding began in August 2023 and will end in late May 2028.

This and other breakthrough research efforts will be discussed in more detail during the upcoming annual meeting of the American Society of Intercellular Communication, (ASICbio.org), scheduled to occur from October 12 to 15, 2023.

Read the full Article Here